BMS-986504 Trial Initiated for Recurrent Glioblastoma Patients with MTAP Loss
A Phase 0/1 trial of BMS-986504 is underway for recurrent glioblastoma patients with confirmed MTAP loss.
Asset / Drug
Drug and asset intelligence for BMS-986504 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.